Results 191 to 200 of about 76,403 (315)

Alisertib and Barasertib Induce Cell Cycle Arrest and Mitochondria-Related Cell Death in Multiple Myeloma with Enhanced Efficacy Through Sequential Combination with BH3-Mimetics and Panobinostat. [PDF]

Cancers (Basel)
Benedi A, Beltrán-Visiedo M, Jiménez-Alduán N, Serrano-Del Valle A, Anel A, Naval J, Marzo I.   +6 more
europepmc   +1 more source

Cytotoxic activity of an interleukin 6-Pseudomonas exotoxin fusion protein on human myeloma cells.

, 1988
Clay B. Siegall, V K Chaudhary, David Fitzgerald, Ira Pastan   +3 more
openalex   +1 more source

Binding of Rabbit Antibodies to a Mouse Myeloma Protein by the Myeloma Cells in Vitro

Experimental Biology and Medicine, 1970
openaire   +3 more sources

The regulatory effects and applications of TIGIT/CD155 on the tumor microenvironment in HCC

VIEW, EarlyView.
Background The interaction between TIGIT and CD155 compromises immune cell efficacy in tumor targeting, potentially driving hepatocellular carcinoma (HCC) progression through diverse molecular pathways. What Was Done This study investigates the interplay between CD155 and TIGIT in regulating CD8+ T cell function and elucidates its implications in HCC ...
Wenting Li, Yukun Li, Yao Li, Mingqi Yang, Haichuan Peng, Hongwei Sun, Ping Jiang, Yizhun Zhu, Qiang Chen, Xiaobing Duan, Wei Zhao   +10 more
wiley   +1 more source

SPAG6 Promotes Multiple Myeloma Through Activation of the MAPK/ERK Signaling Pathway. [PDF]

Front Pharmacol
Li J, Yan X, Ding L, Yin J, Li P, Liu L.
europepmc   +1 more source

CRISPR/Cas9‐edited tumor‐associated immune cells in cancer immunotherapy

VIEW, EarlyView.
Abstract Immuno‐oncology represents an emerging field that has significantly transformed tumor therapeutics, with immune cells serving as the cellular foundations of cancer immunotherapy. Due to its high efficiency and sensitivity, CRISPR/Cas9 genome editing is a highly promising technique for precise and rapid gene modification.
Yuhui Ma, Junxin Chen, Yuan Du, Zhihao Cao, Weizhi Ji, Yuyu Niu, Zebin Yang   +6 more
wiley   +1 more source

Therapeutic Potential of Venetoclax and Selinexor in Targeting Hypoxia-Induced Vulnerabilities in Multiple Myeloma. [PDF]

Cancer Rep (Hoboken)
Okabe S, Arai Y, Tanaka Y, Gotoh A.
europepmc   +1 more source

Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease [PDF]

, 2001
Sun Jin Choi, Yasuo Oba, Yair Gazitt, Melissa Alsina, Jose Cruz, Judith L. Anderson, G. David Roodman   +6 more
openalex   +1 more source

Long‐term survival in a dog with suspected primary nodal plasmacytoma treated with surgical excision

Veterinary Record Case Reports, EarlyView.
Abstract An 8‐year‐old Staffordshire bull terrier presented for left submandibular lymphadenopathy. Cytology showed a monomorphic population of mature plasma cells suggestive of plasma cell neoplasia. On physical examination, no other lymphadenomegaly, cutaneous or oral lesions were found.
Celia Figueroa‐González, Jérémy Béguin, Sarah Stewart, Rachel Garty, Alexandra Guillén   +4 more
wiley   +1 more source

Research progress on N6-methyladenosine and non-coding RNA in multiple myeloma. [PDF]

Discov Oncol
Sun X, Zhou Y, Zhu W, Chen H.
europepmc   +1 more source